AOD9604 2mg/vial Bodybuilding CAS:221231-10-3

   What is AOD9604? Origin and Scientific Foundation

    AOD9604 is a synthetic peptide fragment, comprising the final 15 amino acids of the C-terminal chain of human growth hormone (HGH). It was originally developed by researchers at Monash University in Australia with the goal of creating a compound that retained the beneficial fat-metabolizing properties of HGH without its negative effects on growth and insulin sensitivity.

    The foundational hypothesis behind its creation was to isolate the lipolytic (fat-burning) region of the HGH molecule. While full-length HGH influences growth (via the liver production of IGF-1) and can disrupt glucose metabolism, the C-terminal fragment was believed to operate through a different, more targeted mechanism. Early research suggested it could directly stimulate lipolysis and inhibit lipogenesis (the storage of fat) by acting on pituitary and hypothalamic receptors that regulate metabolism, rather than the growth-promoting pathways.

    The 2mg/vial presentation is a common research concentration, allowing for precise volumetric measurement and administration in experimental settings, typically after reconstitution with bacteriostatic water.

    AOD9604's features are what set it apart from its parent compound and other fat-loss agents. Its mechanism, while not fully elucidated in human clinical trials, is theorized to be unique.

    ●Targeted Metabolic Action: Unlike HGH, which has a broad spectrum of effects, AOD9604 is believed to act specifically on adipocytes (fat cells). It is thought to mimic the way the body naturally stimulates fat breakdown, potentially by binding to a specific fat cell receptor site.

    ●Dual-Action Theory: Research indicates a potential two-pronged approach:

    1.Stimulation of Lipolysis: It may enhance the enzymatic process that breaks down stored triglycerides into free fatty acids, making them available for energy production.

    2.Inhibition of Lipogenesis: Concurrently, it may block the action of enzymes and pathways responsible for converting carbohydrates and sugars into new fat stores.

   ●Absence of Growth Promotion: A critical feature is its hypothesized dissociation from the growth-promoting effects of HGH. It does not significantly elevate IGF-1 levels, which theoretically eliminates the associated risks of acromegaly (bone overgrowth) or organ enlargement.

    ●Potential for Improved Insulin Sensitivity: Some preliminary studies suggest it may improve glucose tolerance and insulin sensitivity, a stark contrast to full-length HGH, which can be diabetogenic. This makes it a compound of interest for metabolic syndrome research.

    In a research context, AOD9604 is investigated for applications that are highly relevant to bodybuilding paradigms. It is crucial to note these are potential applications based on preliminary findings and anecdotal reports from research models, not confirmed human outcomes.

    ●Precision Fat Reduction: The primary area of interest is its ability to potentially target stubborn adipose tissue that is often resistant to diet and exercise alone, such as abdominal, lower back, and thigh fat. This is paramount during contest preparation phases.

    ●Metabolic Rate Enhancement: By potentially increasing the basal metabolic rate through enhanced lipolysis, it could create a more significant daily caloric deficit, accelerating the overall pace of fat loss.

   ●Muscle Preservation in a Caloric Deficit: A paramount challenge for bodybuilders is losing fat without sacrificing hard-earned muscle mass. Some research suggests that AOD9604 may have an anti-catabolic effect, helping to preserve lean tissue during periods of low caloric intake by ensuring energy is derived from fat stores.

    ●Recovery and Injury Healing: Like many peptides, there is interest in its potential role in supporting recovery. Some theories posit it may aid in the repair of cartilage and other connective tissues, though this is less documented than its metabolic effects.

    Based on its proposed mechanism, the potential benefits of AOD9604 for bodybuilding research include:

    ●Targeted Lipid Reduction: Potential for localized fat loss in specific, problematic areas.

    ●Enhanced Definition and Vascularity: By reducing subcutaneous water and fat, it may contribute to a more ripped and vascular appearance.

    ●Improved Nutrient Partitioning: May aid in directing nutrients towards muscle cells and away from fat cells.

    ●Muscle Sparing: Potential to protect muscle tissue during intense cutting phases.

    ●Favorable Safety Profile (Theoretical): The lack of impact on growth or blood sugar in early studies suggests a potentially safer profile than HGH, though comprehensive long-term human data is absent.

    In a research setting, dosing is highly variable. A common experimental protocol derived from available literature involves:

    ●Typical Research Dosage: A daily dose ranging from 300mcg to 1000mcg (1mg) is frequently explored. Many protocols settle on 500mcg per day as a standard research dose.

    ●Dosing Timing: Due to its short half-life (see below), administration is typically performed once daily, often in the morning upon waking or immediately post-workout. Some protocols split the dose (e.g., 250mcg twice daily) to maintain more stable plasma levels.

    ●Cycle Length: Research cycles commonly last between 6 to 12 weeks. This duration is believed to be sufficient to observe potential changes in body composition without desensitization.

    Example for a 2mg/vial:
    For a 500mcg daily dose, a researcher would reconstitute the 2mg vial with 2ml of bacteriostatic water. This creates a solution where 0.5ml (or 50 units on a U100 insulin syringe) contains the desired 500mcg dose.

    ●Half-Life: AOD9604 has a very short plasma half-life of approximately 30 minutes. This is a critical pharmacokinetic property. It means the compound is cleared from the bloodstream rapidly, necessitating frequent administration for sustained effect and ruling out any long-acting or depot mechanisms.

    ●Cycle Structure: A typical research cycle is linear, maintaining a consistent daily dose throughout the period. A common structure is:

    ○Weeks 1-12: Administer 500mcg per day, subcutaneously.

    ○Post-Cycle Therapy (PCT): Unlike anabolic steroids, AOD9604 is not believed to suppress the hypothalamic-pituitary-testicular axis (HPTA). Therefore, a traditional PCT is not considered necessary. Research simply concludes with the cessation of the compound.

    It is imperative to approach AOD9604 with a critical, scientific mindset.

    ●The Efficacy Debate: The human clinical trial data for AOD9604 is limited and mixed. While initial studies showed promise for obesity, a larger Phase IIb trial failed to meet its primary endpoint for weight loss, leading to questions about its efficacy as a standalone anti-obesity drug. However, the bodybuilding community argues that the compound may be more effective in already lean individuals targeting stubborn fat, a hypothesis not tested in large-scale trials.

    ●The "Spot Reduction" Myth: The concept of spot reduction is largely physiologically debunked. The body mobilizes fat systemically based on genetics and hormone receptor density. While AOD9604 may increase overall lipolysis, it cannot exclusively target fat from one specific area without affecting others.

    ●Legal and Regulatory Status: In many countries, including the United States, AOD9604 is not approved for human consumption or as a therapeutic drug. It is sold for "research purposes only" in laboratory settings, not for human use. Its status in sports organizations like WADA is prohibited.

Trade names	Fragment 177-191; AOD 9604 acetate; peptides AOD9604; Peptide HGH 176-191; polypeptide AOD 9604; HGH frag 176-191 Oxidized
CAS	221231-10-3
Molar mass	1815.1
Formula	C78H123N23O23S2
Purity	Above 98%
Apprarance	2mg/vial,Lyophilized powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    AOD9604 2mg/vial represents a fascinating chapter in the ongoing research into metabolic manipulation. It is a compound born from a logical scientific premise: isolating the beneficial fat-loss properties of HGH. Its theoretical features-targeted lipolysis, potential insulin sensitivity improvement, and absence of growth effects-make it a compelling subject for bodybuilding-related research.

    However, its application exists firmly in a gray area of science. The disparity between promising mechanistic theories and mixed clinical trial results necessitates a highly cautious and skeptical approach. For the research community, it remains a peptide of significant interest for exploring the frontiers of fat metabolism and body recomposition. Its true potential and efficacy in a practical context continue to be a subject for further rigorous, ethical, and controlled scientific investigation.

Hot Tags: aod9604 2mg/vial bodybuilding cas:221231-10-3, China aod9604 2mg/vial bodybuilding cas:221231-10-3 manufacturers, suppliers, factory